CoChat

Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial

Open access

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index; 6 of the 11 sources its claims cite were checked for support.

Abstract

Phase II randomized trial of perioperative propranolol and etodolac in pancreatic cancer surgery.

Overview

CoChat Summary

TL;DR

The PROSPER phase II randomized, placebo-controlled trial tested perioperative propranolol plus etodolac around partial pancreatoduodenectomy for pancreatic cancer. It found no safety concerns, but the intervention was not feasible because recruitment was slow and adherence was limited.

Key findings

  • The trial was prematurely closed after screening 1026 patients; 26 were randomized, 20 received trial medication at least once, and only 9 received verum vs. 11 placebo in the final safety set.
  • Safety was acceptable: there were 0 serious adverse reactions and 20 serious adverse events total, with 6 in the treatment group and 14 in the placebo group; the SAE rate was 2.095 times as high in placebo as verum (95%-CI 0.805–5.45; p = 0.1297).
  • Feasibility was poor: adherence was lower in the verum group, with etodolac adherence 50% ± 26% vs. 78% ± 29% in placebo (p = 0.06) and propranolol adherence 47% ± 28% vs. 69% ± 37% (p = 0.20).
  • Preliminary efficacy signals were favorable but exploratory: median DFS was 16.36 months in verum vs. 11.25 months in placebo, and distant recurrence was 11.1% vs. 54.5%, respectively.
  • In translational analyses, verum was associated with a trend toward faster postoperative IL-6 normalization and less loss of immune effectors, while no circulating tumor cells were detected in either group.

Methods

  • Randomized, patient- and observer-blinded, placebo-controlled, phase II trial at Heidelberg University Hospital in patients undergoing partial pancreatoduodenectomy for pancreatic cancer.
  • Patients were randomized 1:1 to perioperative propranolol + etodolac or matching placebo; the planned sample was 100 randomized patients, but the trial stopped early for slow recruitment.
  • Main analyses were exploratory in the safety set; primary safety outcome was SAE rate, primary feasibility outcome was adherence, with OS, DFS, recurrence, morbidity, and translational immune measures also assessed.

Limitations

  • Stated in the paper: the trial stopped early because of slow recruitment, adherence was limited, the cohort was heterogeneous by diagnosis/stage, and only the combination therapy was tested rather than monotherapy.
  • Stated in the paper: translational analyses were incomplete because of shortcomings in specimen sampling and quality.
  • Evident from the text: the final analyzed sample was very small, so all efficacy and translational findings are underpowered and exploratory.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00423-025-03735-3

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Trial flow chart (CONSORT)
Fig. 1 Trial flow chart (CONSORT)CC BY · PubMed Central
Fig. 2 Kaplan–Meier curves for a) overall survival and b) disease-free survival. The analyzed safety set comprises 20 patients of whom 11 received Placebo and 9 received Verum
Fig. 2 Kaplan–Meier curves for a) overall survival and b) disease-free survival. The analyzed safety set comprises 20 patients of whom 11 received Placebo and 9 received VerumCC BY · PubMed Central
Fig. 3 Multicolor flow cytometry (FACS) analysis; Placebo = grey; Verum = red. A Immunophenotyping of patients was performed by multicolor flow cytometry. The absolute numbers of circulating cells for each indicated (sub)-population has been calculated per µL blood and summarized per group in a form of a violin graph. B Time-resolved kinetics have been generated by normalizing measured counts to the individual baselines and consequent log2-transformation of the respective values. Data points are presenting mean values of placebo and verum groups
Fig. 3 Multicolor flow cytometry (FACS) analysis; Placebo = grey; Verum = red. A Immunophenotyping of patients was performed by multicolor flow cytometry. The absolute numbers of circulating cells for each indicated (sub)-population has been calculated per µL blood and summarized per group in a form of a violin graph. B Time-resolved kinetics have been generated by normalizing measured counts to the individual baselines and consequent log2-transformation of the respective values. Data points are presenting mean values of placebo and verum groupsCC BY · PubMed Central
Fig. 4 Box plot of IL-6 levels; Placebo (grey) and Verum (red) groups have been compared using Mann-Witney test
Fig. 4 Box plot of IL-6 levels; Placebo (grey) and Verum (red) groups have been compared using Mann-Witney testCC BY · PubMed Central
Fig. 5 Immune cell quantification: Comparison of CD8 +, CD45 + and CD68 + cell densities between verum (n = 4) and placebo (n = 4) treated patients assessed by whole slide image analysis
Fig. 5 Immune cell quantification: Comparison of CD8 +, CD45 + and CD68 + cell densities between verum (n = 4) and placebo (n = 4) treated patients assessed by whole slide image analysisCC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 0 Not valid · 5 Not checked · 61 Own results and interpretations

24 more claims

Create a free account to see all 72 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 19
  • It may state two separate claims as one. 31

Create a free account to see these claims.

Citations

Cites

Show all 23 references

Cited by

See all 15

Metadata

Authors
Hüttner, F. J., Klotz, R., Giese, N. A., Kong, B., Ahmed, A., Merz, D., Pöchmann, A., Burghaus, I., Hackert, T., Strobel, O., Mihaljevic, A. L., Michalski, C. W., Büchler, M. W., & Diener, M. K.
Affiliations
  • University Hospital Heidelberg (DE)
  • German Cancer Research Center (DE)
  • Heidelberg University (DE)
  • Champalimaud Foundation (PT)
Corresponding author
Diener, Markus K.
Venue
Langenbeck's Archives of Surgery
Published
2025-05-22
Volume
410
Issue
1
Pages
168-168
ISSN
  • 0023-8236 (ISSN-L)
  • 1435-2451
OpenAlex
W4410602717
Cited by
15
References
25
Citations by year
2026: 14 · 2025: 1
FWCI
10.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Langenbeck s Archives of Surgery (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Anticancer Fund (A56)
  • Universitätsklinikum Heidelberg
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
Keywords
pancreatic cancer, propranolol, etodolac, partial pancreatoduodenectomy, beta-blockers, COX-2 inhibitors, disease-free survival, recurrence, medication adherence, serious adverse events, translational research
MeSH terms
Adrenergic beta-Antagonists, Aged, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Propranolol, Pancreaticoduodenectomy, Etodolac, Perioperative Care, Cyclooxygenase 2 Inhibitors, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial. https://app.cochat.ai/papers/10.1007/s00423-025-03735-3
The paper
Hüttner, F. J., Klotz, R., Giese, N. A., Kong, B., Ahmed, A., Merz, D., Pöchmann, A., Burghaus, I., Hackert, T., Strobel, O., Mihaljevic, A. L., Michalski, C. W., Büchler, M. W., & Diener, M. K. (2025). Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial. Langenbeck's Archives of Surgery. https://doi.org/10.1007/s00423-025-03735-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.